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e Antigen in the serum of HB antigen-positive patients on
maintenance dialysis and after transplantation. F. W. Albert, A.
Brisam, G. Traut, G. Thamer. Med. Klinik II, Abt. Nephrologie,
Staedt. Krankenhaus, Kaiserslautern and Abt. für Dialyse und
Nephrologie, Universitüt des Saarlandes, Homburg/Saar and
Med. Universitbtsklinik, Innere Medizin IV, Heidelberg, West-
Germany. The "e antigen" (eAg) is specifically associated with
hepatitis B virus infections and appears to be a marker for the
infectivity and a prognostic for the chronicity of liver disease.
Therefore we examined by immunodiffusion the presence of eAg
in the serum of 22 HB Ag-positive patients on maintenance
dialysis. In 7 of these patients eAG could be detected. eAg was
also investigated in the serum of 51 unselected HB-Ag-positive
patients without any renal failure. This group had a significantly (y
= 6.97; P <0.01) lower incidence of positive eAg (4 out of 51). In
most of the dialysis patients, the microscopic findings of the liver
only revealed "minimal changes." Three eAg-positive patients
received a renal transplant and were treated with prednisone and
azathioprine. Several months after transplantation these 3 patients
displayed an appreciably increased eAg-yield in immunodiffusion.
Histology now revealed a chronic persistent hepatitis. It is as-
sumed therefore that the immunodeficiency of the patients
undergoing chronic hemodialysis can be a supporting effect for the
synthesis of eAg and perhaps induce a more subacute but pro-
longed course of hepatitis. The synthesis of eAg after renal trans-
plantation possibly is enhanced by the additional immunosuppres-
sive therapy.
Hemodialysis-induced leucopenia and activation of complement:
Effects of different membranes. P. Alfama, P. A. E. Bird, M. K.
Ward, T. G. Feest, W. Walker, H. Tanboga, M. Sussman, andD.
N. S. Kerr. University of Newcastle upon Tyne, United Kingdom.
Leucopenia and complement activation occur during hemodialysis
with Cuprophan membrane: Craddock suggests that complement
activation causes the leucopenia. We have tested this theory by
companng the behavior of white cells and complement during
dialysis with different membranes. Total white count, polymorph
count, total hemolytic complement (CH5O), alternative pathway,
factor B (by functional assays), C3 and C4 (immunodiffusion) were
measured atO, 5, 15, 30, 45, 60, 120, 180, and 240 mm from start to
dialysis with Cuprophan 150 (10 patients), wet Cuprophan (7),
AN69 polyacrylonitrile (10), and polycarbonate (7) membranes. A
profound neutropenia occurred within 45 mm with Cuprophan,
wet Cuprophan and polycarbonate membranes (mean nadir 26, 37,
37% of starting value, P < 0.001) and a mild neutropenia (nadir
85%, P <0.01) with AN69. Complement activation occurred over
the same time scale as the polymorph change, but the degrees of
change in CH5O and polymorph count with each membrane were
not related. There was no significant fall in CH5O with polycarbon-
ate (nadir 94%; polymorph nadir 37%) but there was a considera-
ble fall with AN69 (nadir 71%, P <0.001; polymorph nadir 85%),
suggesting that the two phenomena are not cause and effect.
Alternative pathway and factor B assays ran in parallel with CH5O,
showing that activation is mainly through the alternative pathway.
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Effect of saralasin (SAR) on plasma renin (PRA) and arginine-
vasopressin (AVP) in hypertensive man. I. Arlart, H. Wagner, J.
Rosenthal, and H. E. Franz. Medical Center, University of Ulm,
Germany. SAR was found to produce antagonistic and agonistic
effects in patients suffering from hypertensive disease. An antago-
nistic action of SAR has been reported in angiotensin-dependerit
hypertension leading to a significant fall of arterial blood pressure
(BP). This study was carried out to assess the influence of SAR on
peripheral and central angiotensin Il-receptors by measurements
of PEA and AVP release. In 15 hypertensive patients, 80 mg of
furosemide was given orally 12 hr before SAR-application. In the
recumbent patients, blood samples were obtained before and 30
mm after SAR-infusion (10 ig/kg/min) from a peripheral vein for
determination of PRA and AVP by RIA. Systemic BP was moni-
tored continuously. In 10 patients, systolic and diastolic BP de-
creased significantly (P < 0.0005). In this group, PRA was found
to increase significantly (P < 0.0025); in 7 of these patients AVP
levels increased significantly (P < 0.005), and in 3 patients AVP
release was not affected. In 5 subjects out of 15, BP, PRA, and
AVP remained virtually unchanged following SAR. The results
indicate that angiotensin-dependent hypertension can be identified
by the depressor effect of SAR and not by basal peripheral renin
levels. A fall of systemic BP produces a significant increase of
PEA and AVP release. The AVP release may be due to the
hypotensive stimulus. Furthermore, the central stimulatory effect
of All on AVP release is possibly not inhibited by the relatively
low SAR-dose applicable in man.
Comparison of hemodialysis (HD) and post dilution hemoffitra-
tion (HF) on an unselected dialysis population. C. A. Ba/damus,
W. Schoeppe, K. M. Koch. Dept. Nephrology, Univ. Frankfurt!
M., FRG. HD (3 x 6 hr/week; Gambro Optima) was compared to
HF (3 x 20 liters/week; Sartorius Haemofllter or RP 6) in 6 stable,
unselected HD patients (39. 3 : 46—84 kg body wt; 17—63 yr age;
0.5—2.8 ml/min GFR). After >5 months of routine HD, 2 months
of control HD were compared to >4 months HF. Body wt was
kept constant throughout the study. Serum small molecules like
urea (U) and creatinine (CR) increased from HD to HF (U: 165
5110 225 36; CR: 12.9 3.3 to 14.7 3.7 mg/dl), especially in
heavy patients. Serum phosphate (P) rose from 5.9 1.4 in HD to
7.6 1.8 mg/dl in HF. BP remained constant in all patients (HD:
149/90 19/6; HF: 149/88 22/7 mm Hg). Incidence of symoto-
matic BP drop improved from 13.3% in HD to 6.8% in HF,
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whereas incidence of muscle cramps increased from 14.7 to 34%.
The 2 heaviest patients returned from HF to HD after 4 months,
the 1st because of hyperphosphatemia (serum phosphaten, 12 mgI
dl), the 2nd because of lack of well-being, both likely due to
insufficient small molecule removal. U removal during HF fol-
lowed 1st order kinetics. From the ultrafiltration volume (UFV)
necessary to reach a 50% reduction of U(V112) the distribution
volume of U was calculated and found to be equal to the measured
(3H20) total body water (TBW) (V112 = 0.693 x TBW). Conclu-
sions. 1) Hf did not correct hypertension. 2) HF did not correct
hyperphosphatemia. 3) HF offers a less symptomatic fluid re-
moval than HD. 4) HF (3 x 20 liters/week) is an insufficient
treatment for heavy patients with GFR < 1 mI/mm. 5) Small
molecule (U) removal can be standardized by individual adjust-
ment of UFV (V112 = 0.693 x TBW = 0.41 x BW).
1,000 prospective cadaveric renal transplant donors. A. D.
Barnes. Renal Unit, Birmingham, England. In order to perform
450 eadaverie renal transplants in our hospital, it has been neces-
sary to consider more than 1,000 potential cadaveric donors (51%
from the local region) during a nine year period (1968—1977). In the
early years of the series, brain death donors were not available.
Progressively, with the development of intensive care units, the
diagnosis of brain death has been more widely accepted. This is
reflected by the change in the type of patients considered as kidney
donors. During the first 2 years, 75% of the donors were not
treated by I.P.P.R. and a common cause of death was cardiac
(28%). In the most recent year, 63% of the donors were of patients
on ventilators, and 88% of those operated on were on ventilators.
93% of these were certified brain dead, the diagnosis following
head injury in 40% and subarachnoid hemorrhage in 44%. Refusal
by the relatives of consent for the removal of kidneys was 5% of
patients on ventilators but was 25% for patients not on ventilators.
80% of the potential donors offered on I.P.P.R. yielded an average
of 1.7 kidneys, whereas only 20% of potential donors not on
I.P.P.R. yielded an average of one kidney. Using the unit policy of
exporting kidneys via U.K. Transplant for 4 antigen identities and
of transplanting only patients with 2 matching antigens or better,
exports equal imports and account for 44% of kidneys handled by
our unit which covers a population of 5.5 x 106 and performs 70 to
80 cadaveric transplants annually. The paper will also discuss
some of the organization, legal, and medical aspects of cadaveric
kidney donation.
Studies on bicarbonate reabsorption in chronic renal failure
(CRE). A. Borghetti, A. Guariglia, M. Minari, L. Borghi, A. Curd,
A. Montanan, A. Novarini. Istituto di Semeiotica Medica Univer-
sità Parma, Italy. The role of nephron loss, extracellular fluid
volume (ECFV) expansion, K body stores on HCO3 reabsorption
in CRF was evaluated. In 17 CRF and 3 control subjects, tubular
HCO3 reabsorption was studied by HCO3 1M titration technique;
ECFV (22Na space at 4th hour) and cell K content (muscle biopsy)
were also determined. Nephron loss per se does not cause any
change of HCO3 reabsorption rate per unit GFR. With ECFV
expansion induced by HCO3 infusion, a Tm HCO3 is rapidly
reached only in controls and in CRF patients, showing a significant
basal ECFV expansion. In these subjects reabsorbed HCOjNa
ratio is constant, suggesting that, under these conditions, HCO3
reabsorption depends on the same mechanisms that control Na
reabsorption. In cell-K-depleted CRF patients, HCO3 reabsorption
rises more than in controls, and no TmHCO3 is detected at least
within the limits of isotonic ECFV expansion induced by titration;
in these subjects HCO3 reabsorption does not appear limited by
natriuretic factors. In CRF subjects with normal ECFV and cell K,
there is a greater HCO3 tolerance to ECFV expansion induced by
titration technique than in controls.
Is passive immunization against hepatitis B a luxury, danger, or
necessity for dialysis patients and staff? H. C. Burck, P. Berg.
Dept. miens. Care and Dialysis, Krankenhaus, Kiel; Dept. mt.
Med. IL Univ. Tilbingen, Germany. EDTA Reg. Committee re-
ported 6,118 cases of hep.B out of 30,904 RDT patients, with 298
deaths. From 3,922 staff members with hep.B, 57 paid for their
duty with their lives. We have tried to meet this threat. After 2 yr
of successful experience with passive immunization against hep.B
in patients and staff, several questions arise with the commercial
introduction of an expensive gamma-globulin rich in hep.B anti-
body. In the first phase, patients and staff received 4 annual
injections of the highly purified immuglobulin with a anti-HB, titer
of >1:100,000; later injections were timed with monthly control of
anti-HB, titers in the recipients. Before the study, all anti-HB1-
negation RDT patients acquired hep.B (6 out of 7 got chronic
active hep., 1 died). All nurses had become anti-HB6-positive, thus
only new staff was included. As a result of the immunization, there
was no hepatitis in 16 new staff members. Two patients who had
been excluded from immunization acquired manifest hep.B but
recovered. Twenty patients in 2 hepatitis-infected units were im-
munized and did not get hep.B. One unit is free of hepatitis by
now. One patient had a lethal course of hep.B because of ineffec-
tive titers. He possibly died from immunization during the incuba-
tion period. We conclude that patients and staff ought to be
immunized in infected, but not in clean units. Monthly titer control
is important. Time for immunization after infection is limited
because of antibody mediated cytotoxic reactions with great risk
to the patient.
Treatment of psoriasis with dialysis. T. J. Buselmeier, C. M.
Kjellstrand, M. V. Dahl, W. C. Burgdorf, R. L. Simmons, J. S.
Najarian, R. W. Goltz. University Hospital, Minneapolis, Minne-
sota, U.S.A. Our experience, combined with that of Twardowski
and MeEvoy, indicates that dialysis may cure psoriasis. Four
patients (pt) were dialyzed after psoriasis persisted for 10 to 31 yr
despite all available treatment. Two pts remitted after peritoneal
dialysis, one after 2 wks, and another after 2 mos. They remained
clear on chronic hemodialysis 2 and 7 yr later. A 3rd pt remitted
after 2 wks of hemodialysis and remained clear during 1 yr of
hemodialysis and for 1 yr after renal transplantation. A 4th pt
cleared after 5 hemodialyses and remains clear now 4 mos later.
Psoriasis did not recur in any ease. The chronic dialysis pts
received 6-hr dialyses 3 times per week. The others remain clear
despite discontinuance of dialytic therapy. Possible mechanisms
are: 1) removal or infusion of pathologic or physiologic sub-
stances; 2) a sponge-sink effect binding pathologic or physiologic
substances; 3) removal of an inhibitor to epidermal chalone; 4)
stimulation of a change in intracellular cyclic nucleotides; 5) im-
munological activation, inactivation of substances or alteration of
feedback systems; 6) stress-induced hormone production; 7) the
production of an "unphysiological state" (e.g., variations in osmo-
lality or pH). Complement, platelet and white cell aggregation, as
well as osmolality, pH, and trace element alterations, would indi-
cate that these factors may be causative; however, mere exposure
of blood to heparin and the tubing-dialyzer components may be
implicated without regard to the diffusive dialytic exchange proce-
dure per se. Our preliminary data suggests each aspect may be
important.
Calcitonin, bone disease, and chronic renal failure. T. Cundy,
M. Earnshaw, G. Heynen, S. Paton, R. G. G. Russell, D. 0.
Oliver, C. G. Woods, M. Bartlett, J. A. Kanis. Renal Unit,
Chnrchill Hospital, Oxford. Studies previously reported to the
EDTA have suggested that osteitis fibrosa in dialysis-treated pa-
tients with chronic renal failure may be associated with defective
secretion of calcitonin (CT). If the association described were
causally related, then effective treatment of osteitis fibrosa might
be achieved by stimulation of endogenous CT or administration of
exogenous CT. Hormone responses have been measured in 19
patients with osteitis fibrosa before and during treatment with la-
hydroxycholecaleiferol (la-OHD3) for 1 year. In 10 patients in
whom plasma alkaline phosphatase fell to normal, plasma immu-
noreactive CT (iCT) rose and immunoreactive parathyroid hor-
mone (iPTH) fell, whereas, in patients who failed to attain normal
levels, a fall in iVl'H was associated with a fall in iCT. This
suggests that an additional mechanism of action of la-OHD3 may
be to increase enodgenous CT. It is possible that stimulation of CT
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secretion is an essential component of a successful outcome to
treatment. Studies of the use of exogenous salmon CT in 14
patients with chronic renal failure showed that acute hypocal-
caemic responses were proportional to the prevailing level of
'bone cell turnover." These data provide further evidence that
bone resorption can be effectively inhibited when CT levels are
raised either by exogenous CT or its endogenous stimulation.
Clear efficacy of CT on bone resorption has not been demon-
strated with its long term use.
A new predictive factor for the outcome of renal transplantation.
A. A. Diamandopoulos, D. N. Hamilton, and J. D. Briggs. Renal
Unit and University Department of Surgery, Western Infirmary,
Glasgow, Scotland. The cell-mediated immunity (C MI) of patients
on regular dialysis treatment (RDT) was estimated by a modified
dinitrochlorobenzene (DNCB) skin test. The strength of the skin
reaction was called DNCB index, and quantified from 0 to 15 by an
objective scale. Ninety-nine RDT patients (42 in hospital, and 47 at
home) and 16 healthy controls were tested. There were not
significant age and sex differences between groups. The mean
DNCB index of the controls was 8.7, of the hospital RDT patients
it was 1.1 (P <0.001), and of the home RDT patients it was 3.8 (P
< 0.001). Thirty-live RDT patients consequently received kidney
transplants, and these were divided six months later in two groups.
First, those with a functioning graft (22 patients) who had a mean
DNCB index of 0.47 while on dialysis; and second, those who had
rejected the graft and who had a mean DNCB index of 4.2 (P <
0.0001). A good HLA-matching was found to be essential only for
patients with a high DNCB index. The rest could accept even a
badly matched kidney. We concluded that: a) the CMI of RDT
patients is depressed, and this depression is markedly worse for
those dialyzed in hospital than those at home; b) there is a very
strong correlation between DNCB index and six-months graft
survival; and c) only a very well-matched kidney should be offered
to patients with a high DNCB index.
The gut hormone profile in chronic renal failure. C. C. Doherty,
K. D. Buchanan, J. Ardill, and M. G. McGeown. Renal Unit,
Belfast City Hospital and Dept. of Medicine, Queen's University,
Belfast. Hormones removed by the kidney are as important as
those produced by it. The purpose of this study was to examine by
radioimmunoassay fasting plasma levels of five gut hormones—
gastrin, glucagon (total and pancreatic), insulin, secretin and vaso-
active intestinal peptide (VIP)—in normal subjects, patients with
advanced uremia (CRF), and renal transplant patients (RT). The
effect of a single hemodialysis on fasting levels of these hormones
was also studied. There was significant elevation in fasting levels
of gastrin (P <0.0005), glucagon (P <0.0005), insulin (P <0.01),
and VIP (P <0.0005) in CRF patients compared to controls. The
greatest rises were in gastrin and total glucagon. Secretin levels
were unchanged. In 55 RT patients, fasting levels of VIP and
pancreatic glucagon had returned to normal, while levels of gas-
trim, insulin, and total glucagon were decreased compared to the
CRF patients but were still slightly elevated compared to controls.
A single hemodialysis produced a significant decrease in fasting
levels of gastrin (P <0.05) and pancreatic glucagon (P <0.0125)
and a significant rise in plasma VIP (P <0.05). The results suggest
the kidney is involved in excretion of circulating gastrin, glucagon,
insulin, and VIP, but not secretin. The slight elevations of plasma
gastrin, insulin, and total glucagon which persist after transplant
may be due to steroid therapy.
Prevention of upper gastrointestinal complications after kidney
transplantation. C. C. Doherty, M. G. McGeown. Renal Unit,
Belfast City Hospital, Belfast. Because of high mortality rates
from upper gastrointestinal (UGI) complications after transplanta-
tion, many centers carry out prophlylactic vagotomy. The purpose
of this study was to examine the effects of uremia, dialysis, and
transplantation on gastric secretion of acid, and to analyze our
experience of UGI complications after transplantation. One
hundred thirty-one patients with advanced uremia were assessed
by barium meal before transplantation, and 34 had peptic ulcera-
tion (duodenal:gastric, 11:1). Fourteen of these 34 patients have
been transplanted. Three had required surgery prior to transplan-
tation for hemorrhage; of the remaining 11, 6 were given cimeti-
dine and 5 antacids. Only one patient died from UGI complica-
tions. Pentagastrin tests were carried out on 68 patients with
chronic uremia, 38 transplant patients, and 24 controls. Acid
secretion of patients with chronic uremia did not differ significantly
from that of control subjects. Dialysis patients had significantly
higher acid secretions than did controls (P < 0.02), patients with
chronic uremia (P < 0.05), and patients studied more than one
year after transplant (P <0.05). Acid secretion is highest, and the
risk of duodenal ulcer and its complications therefore are greatest
during dialysis and the first year after transplant. UGI complica-
tions after transplantation are largely preventable by 1) thorough
pretransplant gastric assessment, 2) sparing use of steroid, and 3)judicious use of cimetidine.
Aluminium studies in dialysis encephalopathy. H. L. Elliott and
A. I. Macdougall. Renal Unii, Stobhill Hospital, Glasgow, Scot-
land. Aluminium (Al) has been implicated as the cause of the
dialysis encephalopathy syndrome (DES). This study offers fur-
ther evidence of a causal relationship by demonstrating a highly
significant correlation between DES and the Al content of the
water from which dialysis fluid is prepared. A similar correlation is
obtained between serum Al and DES, and in three cases the
subsequent development of DES was predicted from the serum Al
level, despite removal of the patients from further exposure. In
three cases, an abnormally high amount of Al in CSF was found,
and the occurrence of higher Al levels in brains of patients dying of
DES was confirmed. Further studies on bone biopsies, and calcu-
lations of total body Al, calcium, and phosphorus (by neutron
activation analysis) also show an abnormally high Al content,
confirming the reported association between DES and bone dis-
ease. It is concluded that Al is indeed the cause of the dialysis
encephalopathy syndrome, with the major source of Al being the
dialysis water supply.
Sustained negative feed-back between hematocrit and serum-
erythropoietin (SEp) concentration in end-stage renal failure. P.
M. Erbes, H. W. Radtke, W. Schoeppe, K. M. Koch. Dept.
Nephrology, Univ. Hospital, Frankfurt, F.R.G. In a longitudinal
study, the individual course of SEp in end-stage renal failure and
following the onset of regular dialysis treatment (RDT) was inves-
tigated in 15 patients, SEp was determined by use of the fetal
mouse liver cell assay three times in each patients: a) 2—6 months
before the onset of RDT (mean creatinine clearance, 8.3; range, 3—
16 mllminll.73m2), b) on day of first dialysis, c) 2—5 months
following the onset of RDT. The behavior of SEp showed a
uniform pattern: In every patient, SEp increased from a to b
(mean: 229 82 vs. 697 358 (SD) mU/ml, P < 0.001), and
decreased again from b to c (mean at C: 348 146 (SD) mU/ml, P
<0.001). When compared to the mean SEp of 136 65 (SD) mU!
ml of 59 healthy controls, mean SEp levels at a, b, and c were
significantly elevated (P < 0.01). Changes of hematocrit (Hct)
were exactly opposite to changes of SEp. Mean Hct at a, b, and c:
26.1 6.7, 22.6 4.1, and 27.0 3.8 (SD) vol%. The differences
between a and b, and b and c were significant (P < 0.001). The
results demonstrate that even in the terminal stage of chronic renal
failure Ep production is stimulated or suppressed in response to
variations of degree of anemia accompanying progression of renal
insufficiency and institution of dialysis treatment.
Familial Mediterranean fever (FMF) and nephrotic syndrome in
Turkey. E. Erek, K. Onen, A. Miifttiogglu, U. Ulkü, and G.
Akokan. Renal Unit Cerrahpasa Med. Fac., Istanbul, Turkey.
Renal amiloidosis was diagnosed in 16 out of 65 biopsied patients
with nephrotic syndrome between 1971 and 1977. These patients
were positive for all criteria necessary for the diagnosis of FMF.
Presenting symptoms were: abdominal pain and fever in 75%,
arthritis in 20%, and nephrotic syndrome in 5%. Eight patients
were male and 8 were female (age range, 10—35 yr). Fifteen of the
group were Turkish, and the remaining one was Armenian. The
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duration of symptoms varied between 1 year and 16 yr. Labora-
tory tests showed (mean values): 832 mg/100 ml of IgG (490—1300),
85 mg/l00 ml (25—120) of C3, a 24-hr urine IgG of 360 mg (160—
550). Mean values in serum proteins were: albumin, 1.83 g/l00 ml;
alfa-l globulin, 0.28 g/100 ml: alfa-2 globulin, 1.19 g/100 ml; b-
globulin 1.09 g/lOO ml; gama-globulin, 1.03 g/l00 ml. Proteinuna
was massive and nonselective with a mean of 6.5 g/24 hr (1—16 g).
Mean BP was 95/65 mm Hg. (100/85 to 85/55). In 14 of the cases,
immunofluorescent microscopy revealed positive IgG and C3 at
the glomerular basal membrane and the mesangium. In 6 cases,
HL-A patterns were studied, and A2 was present in five. Colchi-
cine (1.5 mg/day) was started in 12 cases. Subjective improvement
in fever and abdominal pain was seen with no effect in proteinuria.
Total parathyroidectomy (PTX) with autograft of parathyroid
tissue in treatment of secondary hyperparathyroidism (SH). U.
Frei, W. Fassbinder, I. Kiempa, K. M. Koch, W. Schoeppe. Dept.
Nephrol. and Dept. Surg., Univ. Hospital, Frankfurt, F.R.G.
Medically-uncontrollable SH necessitates surgical reduction of
hyperplastic parathyroid mass. PTX was performed in 31 of 273
RDT-patients. Indications for PTX were severe symptoms attrib-
utable to SH together with elevated parathyroid hormone (PTH)
levels, exceeding at least 4 sD of the normal mean. From 1970—75,
total or subtotal PTX alone were performed. Since 1976, total PTX
were done together with autotransplantation of parathyroid tissue
into the forearm musculature. The results of PTH after surgery
with the three procedures are shown below:
Elevated
Normal
Subnormal
Clinical course of PTH deficient patients was characterized by
repeated episodes of symptomatic hypocalcaemia 0—4 months
postoperatively as well as after renal transplantation. In all pa-
tients with persistence of elevated PTH levels, secondary surgery
was necessary, three patients had a recurrence of hyperplasia in
the remaining parathyroid tissue or a so far unknown fifth gland,
one patient developed hyperplasia of grafted tissue. Secretion of
PTH from grafted tissue was confirmed by PTH ratios (grafted vs.
nongrafted arm) exceeding 1.5 in seven normocalcaemic patients
and in two patients during dialysis-induced hypocalcaernia. Total
PTX with grafting of parathyroid tissue is recommended as the
treatment of choice when surgical correction of SH is necessary.
Renal origin of a natriuretic factor. J. P. Godon, P. Cambier,
and A. Nizet. Département de Clinique et de Séméiologie médi-
ca/es, Université de Liege, Belgique. Many workers have tried to
define the site of production of the natriuretic factor. The first
purpose of our work was to study the sodium retention of
glomerulonephritis. We have demonstrated that this sodium reten-
tion was due to the disappearance of a natriuretic factor of 45,000
mol wt. Since the only detectable lesions were renal in such cases
of glomerulonephritis, we have postulated the renal origin of such
a factor. We have evidenced that a totally isolated dog kidney
taken from a salt-depleted dog and perfused by blood withdrawn
from another salt-depleted dog, and thus, in conditions in which
the natnuetic factor was absent, produced such a factor after the
perfusing blood was added with saline. Moreover, renal tubular
cells in culture were able to synthesize the same natriuretic factor
if they were taken from salt-loaded rats, whereas this material was
absent in culture medium of tubular cells removed from salt-
depleted normal animals or salt-loaded glomemlonephritic rats.
The same observations were made with renal cortical slices in
vitro. Conclusion, a high mol wt natriuretic material has a renal
origin since it is produced by an isolated kidney and synthesized
by renal tubular cells in culture and cortical slices in vitro.
Pathogenic factor in acute renal failure (ARF). H. U. Gutsche.
Dept. Special Nephrol., University Kiel, West Germany. Re-
cently, a serum factor was detected in ARF patients, which sup-
pressed single nephron GFR by tubulo-glomerular feedback opera-
tion. In order to verify this, serum samples of patients with p.o.
ARF complications were investigated for the presence of this
agent. Control sera were drawn from a) patients with chronic renal
failure, b) patients p.o. with normal kidney function, c) healthy
volunteers. Experimental protocol. Serum electrolytes were re-
moved by dialyzing them against isosmotic mannitol. Feedback
activity was measured in micropuncture experiments on cortical
nephrons of rat kidneys. Stop flow pressure (SFP) was monitored
continuously during perfusion of Henle's loop with deionized sera.
Results. SFP was dropped significantly by sera of 9 patients
containing the agent, scm a through c, however, did not change
SFP when perfusion rates were increased from 10 to 40 nI/mm. It is
still questionable whether this serum factor plays a causal role in
the pathogenesis of certain forms of ARF. There is, however,
indirect evidence that the factor gets into the nephron, since
significant activity has been detected in urine samples of patients
with polyuric ARF. With respect to the factor-induced GFR de-
crease, verapamil (0.04 mg/kg mm, i.v.) as well as theophylline (1
mM intratubular) were highly effective in the rat. Furthermore, the
activity of the factor could be reduced rapidly by albumine-satu-
rated charcoal. High doses of salidiuretics, up to l0- M (i.e.
furosemide), had no effect, which corresponds with clinical experi-
ence in cases of acute renal failure complications.
Pathogenetic mechanisms in tubular renal diseases. H. W. In-
torp, H, Quirrl, and H. Losse. Medizinische Univ.-Poliklinik
Muenster, F.R.G. In earlier studies dealing with immunologic
reactions in pyelonephritis, experimental animals were found to
produce autoantibodies against kidney antigens. To analyze these
reactions, rabbits were immunized with purified preparations of
tubular material. After several injections, these animals produced
autoantibodies as had been found in experimentally induced pyelo-
nephritis. One of the antigens cross-reacted with an antigenic
component of the Escherichia co/i strain 04: :H5 used for experi-
mental pyelonephritis. Immunohistological studies revealed that
this antigen is localized at the cells of the proximal tubular system.
Another antigen was found to be present at the tubular basement
membrane. These antigens also induced cellular immune reactions
as demonstrated by migration inhibition tests. Microscopic studies
Total + Fine-needle aspiration cytology in the prediction and diagnosis
Total Subtotal autograft of acute rejection episodes in man. P. Hdyry and E. von Wille-
(8 patients) (9 patients) (16 patients) brand. Transplantation Laboratory, Fourth Department of Sur-gery, University of Helsinki, Helsinki, Finland. We have corn-
0 2 2 pared a) spontaneous proliferative activity of blood leukocytes, b)
2 4 12 detection of specific killer cells in the blood of transplant recipient,
6 3 2 and c) fine-needle aspiration cytology of the transplant, in moni-
toring acute rejection episodes in renal transplantation. Fine-
needle aspirates of transplants and heparinized blood samples
were taken on day 3, 5, etc., after the transplantation. Sponta-
neous proliferative activity of blood leukocytes was measured by
3H-TdR incorporation, and blood cytotoxic cells were detected by
51Cr release test to relevant (donor) and irrelevant monocytic
target cells in vitro. The spontaneous proliferative activity did not
correlate with the rejection episodes. Specific cytotoxic cells were
frequently seen during rejection episodes in the blood, but were
detected usually on the day of onset or later. T and B lymphoblasts
and tissue macrophages were pathogonomic for rejection, and
were detected as being already in the aspirates on day —3 before
the onset of clinical signs. At the onset of rejection, up to 32% of
mononuclear cells of the aspirate were blasts of either or both
types. As the rejection was successfully treated by intensive drug
therapy, the blast cells and monocytes/macrophages disappeared
from the aspirates. No complications from the aspiration "biop-
sies" were observed and the procedure takes only 60 mm to
perform; we recommend the test as a simple and reliable adjunc-
tion for the differential diagnosis of acute rejection in man.
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of tissue sections from the immunized animals revealed infiltrates
of polymorphnuclear leukocytes as well as swelling of the proxi-
mal tubules and degeneration of mitochondna.
The role of methylprednisolone in the modulation of cellular
cytotoxicity and its relation to renal transplantation. P. Keown, C.
Stiller, R. U/an, C. Lockie, and D. McGirr. Nephrology Unit,
University Hospital, and Dept. of Medicine, U. W. 0., London,
Ontario, Canada. Inhibition of killer-cell generation or suppres-
sion of their cytolytic capacity once formed represent fundamental
mechanisms by which methylprednisolone (MP) may effect modu-
lation of cellular cytotoxicity in the transplant recipient. To evalu-
ate these possibilities, the in vitro effect of therapeutic concentra-
tions of MP (0.001—100 sg/ml) on cell-mediated cytotoxicity
generated both in vitro in mixed lymphocyte culture and in vivo
following renal allotransplantation was assessed. The presence of
MP (0.001—1 g/ml) during the sensitization stage resulted in
suppression of lymphocyte activation without cytolysis, and
marked or total inhibition of killer-cell generation. Considerable
individual variation was seen, which appeared to be a characteris-
tic of the responder cell and directly related to its cytotoxic
capacity. Killer-cells, once generated in vitro were refractory to
suppression. Allograft recipients demonstrated specific unrespon-
siveness on donor stimulation, but a normal response and suppres-
sion (0.001—I sg/ml) on third-party stimulation. Killer-cells gener-
ated in vivo appeared to exhibit a dual response, correlating with
the clinical course, and were either sensitive (10—20 g/ml) or
resistant (200 g/ml) to MP. Thus, MP may exert its effects by
both proposed mechanisms, and the cellular sensitivity may be
reflected in the clinical response.
Long-term observation of ocular findings after renal transplan-
tation. H. Kopsa, H. Bette/heim, G. Grabner, P. Schmidt, J.
Zazgornik, P. Baicke, and P. Pils. 1st Medical Clinic and 2nd
Ophthalmic Clinic, University of Vienna, Austria. Fifty-one renal
transplant recipients with a total of 66 transplants were checked
for ocular changes within a mean observation period of 31.1(1—77)
months after surgery. Ocular investigations included slit-lamp,
tonometry, fundoscopy, ophthalmodynamometry and opthalmo-
dynamography. Twenty-six patients were checked twice (11.4 [1—
28] months and 19.4 [7—40] months, respectively) after transplan
tation; 19 cases additionally were examined 52.9 (5—77) months
after surgery. Only 10 patients (19.6%) were free from ocular
disorders. The most common complication was steroid cataracta
in 22 (44%) controlled patients and in 8 (42.1%) three-times-
reexamined recipients. A severe steroid glaucoma was seen in one
case during rejection crisis and hepatic insufficiency. One other
case showed elevated ocular pressure (max. 24/22 mm Hg) during
13 months after transplantation despite vigorous pilocarpine ther-
apy. Two further cases had moderately increased ocular pressures
temporarily (20/20 and 22/22 mm Hg—both, however, under
chronic Catapresan' therapy). Recurrent subconjunctival hemor-
rhages were seen in 14 cases, and calcium deposits in the conjunc-
tival tissues were seen in 16. Fundoscopy revealed pigmentary
irregularities in the foveolar region in 11, narrow arterial vessels in
18, and pale papillas despite normal RBC in 5 transplants. Long-
term results of the 19 cases examined three times did not show any
correlation between frequency of cortisone cataracta and duration
or dosage of steroids administered, or serum cholesterol or serum
calcium levels. Ocular complications after renal transplantation
are of high incidence (80.4%), yet it should be stressed that
impairment of visual function could not be observed in our mate-
rial. Despite severe hypertension in 21 patients, no hypertensive
retinopathy was found.
HBAg immunecomplex glomerulonephritis (GN). A. L'Abbate,
F. Bartolomeo, V. Misefari, Q. Maggiore. Centro Fisiologia C/in-
ica C.N.R., Reggio Cal., Italy. We looked for HBAg immuno-
deposits on kidney biopsies of 100 consecutive patients (pts) with
GN of various type. Ten pts were HBAg-serum-positive by RIA,
but none of these showed HBAg immunodeposits within the
kidney at direct immunofluorescent examination. By contrast,
glomerular deposits of HBAg along with Ig's and complement
factors were found in 5 HBAg-semm-negative pts, four with
mixed cryoglobulinemia (MC) of IgG-IgM (k) type and one with
lupus eiythematosus GN. Anti-HB were detected in the serum of
three MC pts. The IgG component of ciyo-Ig's obtained by Sepha-
dex G-200 chromatography gave positive RJA reaction for either
anti-HB and HBAg. The latter, having a higher partition coeffi-
cient than that of the reference '25I-HBAg, was likely an immuno-
reactive fragment(s) of HBAg. Immunocomplexes were in anti-
body excess since 60% of '25I-HBAg added to MC serum
precipitated with the cryo-lg's. HBAg immunocomplexes may led
to GN being often associated with MC.
A new aspect concerning uremic hemolysis: Increased suscepti-
bility to peroxidation! H. W. Leber, R. Spiegelhalter, and G.
Schtitterle. University Hospital, Giessen, W. Germany. During the
autoxidation of hemoglobin in erythrocytes, hydrogen peroxide is
continuously generated. Investigations were undertaken to find
out, whether an augmented peroxidative damage attributes to the
increased hemolysis observed in chronic uremia. Erythrocytes
from chronic uremic patients and controls were incubated (37°C, 3
hr) in phosphate buffer containing 166 mmoles H2O2/liter (pH, 7.4;
300 mOsm/liter). Without H2O2 no hemolysis was detectable. In
the presence of H202, the hemolysis rate of normal cells was
significantly lower (2.0 0.1%) than with uremic cells (12.1
1.0%). Uremic cells withdrawn after dialysis had a lower hemoly-
sis rate than before dialysis. In the presence of H2O2, lipid peroxi-
dation (investigated by measuring malonedialdehyde production)
increased to 280% both in normal and uremic erythrocytes. During
the incubation, lipid peroxidation was not correlated with the
degree of hemolysis. It is concluded that erythrocytes from uremic
patients are more susceptible to peroxidation than normal erythro-
cytes. Therefore, H2O2-producing drugs should be avoided in
uremia. The increased peroxidative hemolysis is due to unstable
hemoglobin molecules and/or impaired H2O2 degradation rather
than to augmented peroxidation of membrane lipids.
Scanning electron microscopic study of hyperacute rejection in
the inbred rat. C. Leithner, H. Piza-Katzer, P. Kruzik, M. Winter,
W. R. Mayr, H. Stachelberger, and H. Sinzinger. Vienna Medical
School, Univ. of Vienna and Technical Univ., Vienna, Austria. As
to our knowledge, a study on hyperacute rejection of renal trans-
plants using the scanning electron microscope (SEM), which pro-
vides very informative pictures, has not been performed. 20 skin-
presensitized Lewis rats received kidney transplants from (Lewis
x BN) f1 rats. Two grafts each were taken for examination at
intervals from 1, 2, etc. to 120 mm and were compared with series
of Lewis-to-Lewis isografts. Just at 1 mm, spider-like fibrin fibers
and thrombocytes attached to the wall of small arteries and arteri-
oles occurred. The endothelial cells were in part disconnected and
in a stage of desquamation. At 5 mm, a network of fibnn devel-
oped, containing mechanically injured erythrocytes, neutrophils,
and platelet aggregates. These changes aggravated with time and
resulted in a complete vascular occlusion at 60 mm. The glomeru-
lar podocytes showed hemispheric protrusions and fiber-like mate-
rials between their processes. It is obvious that the immunological
attack in hyperacute rejection causes a sudden and heavy endothe-
hal damage, which is followed immediately by intravascular
coagulation.
Enhanced prostacyclin availability of blood vessels in uremic
humans and rats. C. Leithner, M. Winter, K. Silberbauer, 0.
Wagner, W. Pinggera, and H. Sinzinger. 2nd Dept. of mt. Med.,
Dept. of Gastroent. 1st Dept. of Surg., Univ. of Vienna, Austria.
Recently prostacyclin, an instable prostaglandin with strong inhibi-
tory effect on platelet aggregation, has been demonstrated in the
walls of blood vessels. In regard to the known dysfunction of
hemostasis in uremics, we estimated the prostacydin availability
of arteries and veins of 10 uremic patients and 12 nephrectomized
rats. For this purpose, vascular samples were incubated in Tris
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buffer. Then the inhibitory effect of the supematant on ADP-
induced platelet aggregation in platelet-rich plasma was measured.
Vascular samples of kidney donors and healthy rats served as
controls. The basal release of prostacycin by the uremic vessels
was insignificantly increased. The availability of the "unstable
compound" after long-term incubation of the tissues was, how-
ever, distinctly increased and prolonged. These results were quite
similar in human and rat materials. These findings suggest that the
significantly increased and prolonged prostacydin availability
from uremic blood vessels is a key mechanism for the deterioration
of hemostasis in uremics.
Sorbent peritoneal dialysis. A. Lewin, A. Gordon, M. B/omen-
krantz, M. Roberts, E. Pecker, J. Coburn, and M. Maxwell.
Cedars-Sinai Medical Center, VA Wadsworth Hospital Center &
UCLA School of Medicine, CCI Life Systems, Los Angeles,
Calif., U.S.A. Current techniques of peritoneal dialysis (PD) re-
quire large volumes of solution usually supplied via multiple bot-
tles, large sterile containers, or dialysate concentrate mixed with
sterile reverse osmosis water by proportioning systems. The use of
sorbents for regeneration of peritoneal dialysate would permit a
complete PD using only 4 liters of commercial dialysate which is
continuously regenerated. After successful animal studies, initial
clinical trials were complicated by septic and aseptic peritonitis.
These were resolved by reducing sampling, utilizing specially
designed tubing sets, eliminating pyrogens, and adjusting the pH.
Recently, a unit specifically designed for sorbent PD was made
available. The fluid system is sterile and disposable. Dialysate is
administered at 300 mI/mm and removed at 150 mI/mm so that 2
liters is exchanged every 20 mm. Dialysate calcium, magnesium,
and dextrose are reconstituted by post-cartridge infusion. Re-
peated PD have been performed with the expected reduction in
urea, phosphate, and creatinine and without complications. The
present unit is 51 x 46 x 43 cm and weighs 25 kg. The production
unit will be smaller and lighter. Further miniaturization can lead to
a wearable system for continuous PD.
Ultrafiltration and high sodium concentration dialysis: Patho-
physiological correlations. F. Locatelli, R. Costanzo, S. Di-
Filippo, L. Pedrini, P. Marai, C. Pozzi, R. Ponti. Nephrology and
Dialysis Unit, Hospital of Lecco, Italy. The aim of this study is to
verify if the capacity to lose remarkable weight by the patient
without negative collateral effects using ultrafiltration depends
either on a nondialysance of hypertensive substances or, on the
other hand, if it depends on pathophysiologic mechanism caused
by ultrafiltration which do not bring about a fall in plasma sodium
and osmolality in comparison with standard hemodialysis with
dialysate sodium concentration between 135 and 140 mEq/liter.
Five patients have been subjected to a dialytic strategy consisting
of 3 sittings weekly of 4 hr each with Gambro Ultradiffuser filter.
The first hour was carried out only with ultrafiltration, obtaining an
average decrease in weight of 3500 g; the following 3 hr were
carried out with dialysate sodium concentration of 140 mEq/liter.
The same patients then underwent a successive dialytic strategy
consisting of 3 sittings weekly of 4 hr each with a dialysate sodium
concentration during the first hour equal to the pathophysiologic
situation realized by the ultrafiltration, bearing in mind therefore
the index of extraction of the sodium with ultrafiltrate which is
0.946 and the decrease in average concentration of the urea in the
first hour. The average concentration of sodium in the dialysate
during the first hour was 155 mEq/liter. With this strategy in the
first hour the same average decrease in weight as with ultrafiltra-
tion was realized. The results did not show differences between
the two strategies as regards tolerability to dehydration. For this
reason, these results underline the pathophysiologic role of stabil-
ity of plasma sodium and osmolality in the patient's capacity to
tolerate high dehydration and would tend to minimize the role of
nondialysance of hypertensive substances.
Human polyoma virus: A significant pathogen in renal trans-
plantation. E. F. D. Mackenzie, B. Amer, J. M. Poulding, P. R.
Harrison. Southmead Hospital, Bristol, England. The Human
Polyoma Virus BK. (HPV) is a recently identified virus infection
in renal allograft recipients. This virus infects urothelial cells, and
these are easily demonstrated by exfoliative urinary cytology. A
rapid method for specific diagnosis has been developed by pro-
cessing the urinary sediment for electron microscopy. This was
confirmed later by serology and virus isolation. Six cases of HPV
infection have been detected by routine daily screening of the
urine from 53 consecutive renal allografts (11%). The virus was
never found within a month of transplantation. One patient died
21/2 months after transplantation from widespread opportunistic
fungal infection. In three other cases, transplant nephrectomy was
performed due to chronic rejection, and only one of the two
surviving kidneys is functioning well. In two allografts, ureteric
stenosis appeared to be related to the virus infection. In all cases,
increased immunosuppressive drugs had been used for rejection
episodes. It seems that HPV is another opportunistic virus infec-
tion which occurs in immunosuppressed patients and is associated
with a poor graft prognosis.
Cessation of bone loss in chronic renal failure by 1-alpha-hy-
droxyvitamin D3: A controlled trial. S. Madsen, K. Qlgaard, and
J. Ladefoged. Nephrological Dept. P, Rigshospitalet, Copen-
hagen, Denmark. The study was undertaken in renal patients in
order to evaluate 1) the degree and course of skeletal deminerali-
zation and 2) the possible effect on the bone mineral content
(BMC) of long-term treatment with ln-hydroxyvitamin D3 (la-
OH-D3). BMC was measured on the radius by 241Am-photon-
absorptiometry, and the results were corrected for age, sex, and
bone width. In a longitudinal and cross-sectional study, BMC was
measured in 191 normal subjects and in 88 renal patients. In a
controlled trial, 22 of the renal patients were treated for 20 months
with la-OH-D3, while 22 renal patients did not receive vitamin D
supplements. In renal patients, an accelerated bone loss (—3%/yr)
and a significantly reduced BMC (mean 87.2% of normal) was
found. In the la-OH-D3-treated patients, BMC increased on an
average 0.5%/yr. This was significantly different from the contin-
ued bone loss (mean, 3. 1%/yr) recorded in the nontreated control
patients. The data indicate that 1) renal patients via accelerated
bone loss develop reduced bone mass, and 2) cessation of this
bone loss is achieved by long-term treatment with la-OH-D3.
Evaluation of plasma neurotoxin concentration in uremic poly-
neuropathic patients. N. K. Man, G. Cueille, J. Zingraff, P.
Jungers, A. Sausse, J. Boudet, and J. L. Funck-Brentano. Dé-
partement de Néphrologie de l'hôpital Necker, Paris, France, et
Laboratoires de Recherches de Rhône-Poulenc Industries, Paris,
France. Purification of b4_2 sub-peak obtained on DEAE Sepha-
dcx A 25 chromatography gave us the possibility to quantify the
plasma concentration of the neurotoxin present in uremic patients
with active polyneuropathy. During all the purification procedure.
it has been verified that, at each step, the neurotoxicity of the
product measured by the in vitro frog sural nerve test was pre-
served. From the purified neurotoxin isolated by kieselguhr and
cellulose chromatography, we calibrated analytic columns for b4_2
analysis. Plasma concentration, measured in 6 uremic neuropathic
patients, is between 13 and 19 mg/liter. In 33 uremic patients
without neuropathy, the plasma concentration is between 13 and
19 mg/liter. In healthy subjects the plasma concentration is less
than I mg/liter. The neurotoxin weekly removal in uremic patients
without neuropathy, treated by a 5-hr RP6 session three times a
week, is of the same order of magnitude than the weekly urinary
excretion in healthy subjects. Preliminary results on a tentative
identification of this purified product indicate that it is not a
polypeptide but an acidic-polyol derived from carbohydrate
metabolism.
Cytogenetic analysis on children born of parents treated with
immunosuppressive drugs. M. G. McGeown, N. C. Nevin. Renal
Unit, Belfast City Hospital and Department of Medical Genetics,
Queen's University, Belfast. Kidney transplant patients wishing to
become parents are concerned about the possible effect of drugs
on the fetus, as are patients treated with immunosuppressive drugs
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for other reasons. It has been stated that there is no evidence of
increased risk of fetal abnormality despite other reports of congen-
ital malformations. We have carried out cytogenetic analysis on
the offspring of 2 women previously treated with cyclophospha-
mide for glomerular disease, and of 7 men receiving azathioprine
and prednisolone following kidney transplantation. The 2 women
who had received cyclophosphamide had 7 babies after treatment.
All the babies were normal and had normal chromosome constitu-
tion. The 7 male patients fathered 9 children. All except 1 were
normal and had normal chromosome constitution, the exception
being a mongol. The father of the mongol has since fathered a
normal child. In the 15 normal children, there was no evidence of
chromosome breakage, increase in chromatid, isochromatid gaps
or breaks or dicentric chromosomes. Patients who wish to attempt
parenthood after treatment with cyclophosphamide or while re-
ceiving azathiopnne may be reassured that there is a very strong
likelihood of the child being normal. Where there may be special
anxiety as in our patient whose first child was a mongol, trans-
abdominal amnicocentesis can exclude an open neural tube defect
by normal amniotic fluid alphafetoprotein level, and cytogenetic
analysis will exclude mongolism.
Rupture of the allograft kidney: Is repair possible? F. Montes,
P. McMaster, R. I'. Caine, and D. B. Evans. Department of
Surgery, University of Cambridge, Addenbrooke's Hospital,
Cambridge, United Kingdom. Spontaneous rupture of the allograft
kidney is an uncommon complication, and transplant nephrectomy
is usually recommended. The results of our experience with 13
major kidney ruptures in 12 of 419 transplant patients (2.8%) is
reported. Nine spontaneous ruptures occurred in <22 days post-
transplant. Clinical features were oliguria, pain, swelling of the
graft site, and signs of hemorrhage. In 5 of these patients, repair
was possible, and mean kidney survival was 47.8 months. One of
the 9 patients died, and this followed transplant nephrectomy and
hemorrhage. We found no one factor to be responsible, but the
most important features appeared to be ischemic damage, rejec-
tion, and ureteric obstruction. All patients with evidence of ure-
teric obstruction had repair and pelvic nephrostomy. Four delayed
ruptures occurred on days 30, 31, and 39, and at 41 months
(second rupture), and here the clinical picture was less consistent.
In 3, repair was possible with good subsequent renal function,
although 2 eventually died of pulmonary sepsis. We suggest that an
acute awareness of this condition with prompt renal exploration
allows a careful evaluation of the factors responsible for renal
rupture. In many kidneys conservative repair may be possible with
successful preservation of the allograft.
Androgen trial in renal anemia. R. B. Naik, A. R. Gibbons, 0.
H. B. Gyde, B. R. Harris, B. H. B. Robinson. East Birmingham
Hospital. A double-blind crossover trial of nandrolone decanoate
was completed in 22 adult patients with anemia due to end-stage
renal disease and stabilized on dialysis. After informed consent,
placebo or 200mg of the drug was given i.m. weekly for 6 months.
Then a 6-week washout' period was followed by 6 months of the
alternative treatment. Flematinics were given but no transfusion
was done. Regular investigations included blood counts and serum
iron and liver function tests. Red cell 2-3-diphosphoglycerate and
oxygen dissociation (p50), serum ferritin and erythropoietin, red
cell mass, and plasma volume were measured before and after
treatments. There was no sustained significant rise in hemoglobin
concentration or in red cell mass. Fluctuations were due to blood
loss. A small rise in 2-3-diphosphoglycerate was not paralleled by a
shift in the oxygen dissociation curve (p50) or a change in exercise
tolerance. Erythropoietin levels did not alter and were within the
normal range, but were lower than would be expected for the
degree of anemia. Evidence of inhibition was present in three
patients. A majority reported increased well-being, including exer-
cise tolerance, appetite, and libido. Voice changes and hirsutism
were noted, mainly in the females. Some instability of anticoagu-
lant therapy was troublesome. One patient had transient minor
changes in the liver function tests. Benefits, though real, were
restricted essentially to the improvement in subjective findings and
were unrelated to laboratory measurements. These effects might
be obtained with a lower dosage of the drug.
Partial protection against acute renal failure (ARF) in rats with
reduced renal mass (RRM). R. Perez-Garcia, J. M. Lopez-Novoa,
and L. Hernando. Fundación Jiménez DIaz, Madrid, Spain. GFR
reduction mechanisms in ARF are as yet unknown. The major
determinant of the decrease of GFR in the experimental ARF
glycerol model is the reduction of glomerular plasma flow (PF). An
increase in single nephron GFR and PF is observed when the renal
mass is acutely reduced. Both situations are opposite in nature.
Therefore, a study of the evolution of the glycerol-induced ARF on
rats with RRM was conducted. Experiments were performed on
101 female adult Wistar rats. ARF was induced by i.m. injection of
50% glycerol, 10 mI/kg body wt., 48 hr after the following opera-
tions: unilateral nephrectomy (group A); unilateral nephrectomy
and resection of 'J of the remnant kidney (group B), and sham
operation (group C). Inulin and PAH clearances, renal renin con-
tent, and plasma creatinine measurements were performed. Stud-
ies concerning the influence of diuresis and natriuresis per nephron
on the development of the ARF were also carried out. The animals
with RRM showed a partial protection against ARF. Plasma creati-
nine reached 1.99 0.23 mgldl in the group A, 1.70 0.26 in the
group B, and 3.62 0.31 in the group C, 48 hr after ARF
induction. Renin does not seem to be involved in this protection.
An increased natriuresis per nephron partially protects against
ARF. An increased PF per nephron in animals with RRM seems to
play a major role in the protection observed.
The cause of inadequate hemodynamic reactions during ultra-
diffusion. H. Pogglitsch, Ii. Holzer, J. Wailer, H. Pristautz, H.
Leopold, H. Katschnig. Med. Univ. Clinic Graz, Austria. Using
the continuous measurements of blood density as an excellent
method to follow-up fluid shifts, we studied the relationship be-
tween volume regulation and hemodynamics in 30 dialysis patients
under conditions of pure ultrafiltration and ultradiffusion. 1) A
fluid withdrawal of 4000 915 cm5 by ultradiffusion leads to a less
pronounced reduction of blood volume than a fluid loss of 3900
1069 cm3 by ultrafiltration (330—450 cm3, as compared to 700—940
cm3) but to a significantly higher reduction of the mean art. blood
pressure (—41 15 mm Hg, as compared to 13 10mm Hg) and
peripheral vascular resistance (—429 500, as compared to +223
410 dyn sec cm5). 2) The blood pressure fall is the result of
an active regulatory process of the volume regulation, influenced
by the hydration state, plasma protein concentration, and hemody-
namic efficency of the patient. 3) The insufficient peripheral vascu-
lar constriction during ultradiffusion seems to have its reason in an
elavation of the threshold of sensation for vasoconstrictory stimuli
of the sympathetic nervous system, caused by hypocalemia and
hypercalcemia developing in the course of effective hemodialysis.
4) In most cases, the threshold can be restored by infusion of
potassium (5—10 mval per 15—30 cm3).
Hemodialysis and peritoneal dialysis treatment of patients with
diabetic nephropathy: A comparative study. E. Quellhorst, B.
Schuenemann, G. Mietzsch. Nephrological Center Niedersach-
sen. W. Germany. 32 patients with chronic renal insufficiency
(CR1) due to juvenile onset diabetes mellitus have been submitted
to dialytic treatment: 16 with intermittent hemodialysis (group A)
and 16 with peritoneal dialysis (group B). Both groups were similar
with respect to onset of diabetes, course of RI, start of treatment,
percentage of patients with hypertension, and duration of dialysis
treatment (382 and 389 patient-months, respectively). In compari-
son to group B, patients of group A showed a more rapid progress
of neuropathy, retinopathy, and visus loss. Hypertension could be
influenced to a considerably higher degree by hemodialysis than by
peritoneal dialysis. Six patients of group A and 5 patients of group
B died after a dialysis treatment of 3 to 30 months. In patients of
group B and a comparative group of non diabetic chronic perito-
neal dialysis patients (group C), the dialysances (D) of urea and
inulin were measured before, during, and after the administration
of sodium nitroprusside and dipyridamole. Nitroprusside induced
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a significant increase in D inulin and a small increase in D urea in
group C, whereas both dialysances were raised insignificantly in
group B. Dipyridamole showed an effect only in group B, in which
D urea increased to a higher percentage than D inulin, but did not
effect dialysances in group C. The results give evidence for a
considerably reduced peritoneal diffusion coefficient in diabetics
compared to patients with CR1 of other origin, which can be
improved, however, by drug administration.
Vascular factors in the pathogenesis of uremic bleeding. G.
Remuzzi, T. Bertani, M. Livio, A. E. Cavenaghi, M. Mysliwiec, D.
Marchesi, G. Mecca. Nephrology and Dialysis Division, Ospedali
Riuniti, Bergamo, Italy, and Mario Negri Institute, Milan, Italy.
The role of vascular factors in the bleeding tendency of uremic
patients is poorly understood. We therefore studied in venous
biopsies from uremic patients the 3 major factors of the hemostatic
system normally present in vascular tissues: factor VIll-related
protein (F-VIII), plasminogen activator (PA), and prostaglandin 12
(P012). F-VIII, detected by immunofluorescence, was equally
present on the vascular intima of both 13 patients arid 11 normal
subjects. Similarly, comparable values of PA, determined histo-
chemically, were found in tissue slices of both 7 patients and 7
controls. In contrast, PGI2 activity, measured as platelet aggrega-
tion inhibitory potency, was significantly increased (up to 60 times)
in the specimens from 15 patients with either acute or chronic
uremia, as compared with 10 controls. It normalized in 3 patients
with acute uremia concomitantly with restoration of the renal
function. Bleeding time, a reliable in viva parameter of bleeding
tendency, was variably prolonged in all patients and did not corre-
late either with F-VT!! or with PA. In contrast, the longer the
bleeding times, the higher the PGI2 activity. Among the vascular
factors considered, the selective increase of P012, the most potent
physiological inhibitor of platelet function, strongly suggests that
the disturbed hemostasis of uremic patients be due to impaired
platelet-vessel wall interaction.
Comparison of intermittent with continuous peritoneal dialysis.
M. Robson, D. G. Oreopoulos, S. Clayton, S. Izatt, A. Rapoport,
and G. A. deVeber. Toronto Western Hospital, Toronto, Ontario,
Canada. Eighteen patients (6 men, 12 women; ages, 21—74 yr) who
had been on chronic intermittent peritoneal dialysis (IPD, 40 hr/
wk) for an average period of 19.6 months (1 to 45 mo.), were
converted to continuous ambulatory peritoneal dialysis (CAPD, 2
liter exchanges, 4 times a day, 6 days a week). CAPD was per-
formed with the use of commercially available dialysate in 2-liter
plastic bags (Baxter-Dianeal), connected to the permanent cathe-
ter by a short plastic tube. After inflow, the bag, still attached to
the connection tube, is carried rolled up in a cloth waist purse
under the clothing. After 6 hr, dialysate is drained into the bag, the
bag is discarded, and a fresh bag is attached to the same connec-
tion tube. All patients showed a dramatic biochemical improve-
ment manifested only a few days after they had been on CAPD.
Serum creatinine and BUN values decreased to levels averaging
70% to 85% of pre-CAPD values, respectively. CO2 values re-
turned to normal in all, while Hb increased by 1—2 g/lOO ml in most
patients. There were no significant changes in serum albumin. All
patients preferred CAPD to IPD because of "freedom from a
machine," increased well-being, and access to a normal diet.
Weight, blood pressure, potassium and phosphorus control were
much easier on CAPD than IPD. During a total of 32.8-month
patient period, there were 4 episodes of peritonitis, and incidence
only slightly higher than observed on IPD. We concluded that
CAPD, using the technique described above, is superior to con-
ventional IPD.
Long-term results in children following dialysis and renal trans-
plantation. L. ROhl, K. Dreikorn, H. W. Schdler, H. W. Asbach,
R. Horsch. Dept. of Urology, Surgical Center, University of
Heidelberg, F.R.G. Seventy-nine children in end-stage renal dis-
ease (43 girls and 63 boys; mean age, 11 3 yr) have been treated
in our department since 1969, covering 214 dialysis-years and 45
transplant-years, respectively. In 35 children, 36 transplantations
have been performed, using living donors in 4 cases. Of 6 children,
4 died in the early postoperative course from cardiac failure and
(pulmonary) infection, 2 in the late phase (3 resp. 4 years after
TPL) from cardiac failure and meningitis (overall mortality, 17%).
In addition, 6 grafts had to be removed for irreversible acute
rejection. One child died after reinstitution of dialysis. The remain-
ing 5 children are presently waiting for a second transplantation.
Twenty-two transplants show a satisfactory function. So far, 44
children have been treated by hemodialysis alone. Seventeen of
these had been referred to our hospital after initiation of dialysis
(mortality, 47%). In 27 children, hemodialysis had been initiated in
our hospital (mortality, 44%). According to our experience, an
integrated program of dialysis and early transplantation is the
treatment of choice for children in terminal renal failure with
regard to survival rate and rehabilitation.
Importance of the hourly plasma refilling rate in the genesis of
hypovolemic hypotension during sequential ultrafiltration and di-
alysis (SUD) and regular dialysis (RD). J. J. Rouby, J. Rottem-
bourg, J. Y. Basset, J. P. Durande, andM. Legrain. Hôpital de La
Pitié, Paris, France. Hourly plasma refilling rate (HPRR) is de-
fined as the difference between directly measured hourly ultrafil-
tration (UF) and hourly variation in plasma volume using the 51Cr
technique. The 2 methods SUD and RD were sequentially per-
formed in 8 patients using a Rhodial-75 Na bath: 138. Plasma
osmolality remains constant during UF period with SUD and
decreases (mean, 22 mOsmoles) during RD. High HPRR (65% of
UF) explains the moderate hypovolemia (average, 600 ml) despite
high UF during the first hour of SUD (average, 1700 ml). With RD,
HPRR is low during the first hour (40% of UF) and increases to
reach 86% of UF at the end of the fourth hour. Presence or
absence of water shift towards the intracellular fluid in relation
with a decrease in plasma osmolality can explain the sequential
values of the plasma refilling rate during the first hour of SUD or
RD. Despite moderate UF, a low HPRR can induce severe hypo-
volemia and hypotension. UF should not be too rapid using SUD
even in overhydrated patients. UF should be moderate during the
first hour of RD.
RD 145 40% 458 77% 392 86%
SUD 1700 65% 603 104% 285 UF = 0
Significance of vascular anomalies in human renal transplanta-
tion. J. R. Sansom, C. L. Hall, J. D. Blainey, B. H. B. Robinson,
and A. D. Barnes. Artificial Kidney Unit, Queen Elizabeth Hospi-
tal, Birmingham, England. To determine the primary failure rate
(PFR) and the incidence of anastomotic hemorrhage (AH) and
urinary leak (UL) in transplanted kidneys with an anomalous
blood supply, a retrospective study of 250 consecutive human
cadaver kidney transplants was carried out. Sixty-two transplants
had multiple renal vessels, whereas 171 had a single renal artery
and vein. There were 13 early deaths and inadequate records in 4
cases. The PFR and the incidence of AH and UL were signifi-
cantly increased in the abnormal group:
Renal vessels No. PFR, % AH, % UL, %
Abnormal 62 36.7 8.1 8.1
P <0.001 <0.01 <0.05
Normal 171 16.2
Moreover, the PFR due to vascular thrombosis, in the absence of
any histological evidence of rejection, was 24.2% in the abnormal
group and 4.1% in the normal group (P < 0.001). These data
indicate that the transplantation of kidneys with multiple renal
vessels, which comprise 25% of donor kidneys, is associated with
a doubling of the PFR due to a six-fold increase in renal vascular
thrombosis and a significant increase in vascular and urological
First hr Second hr
HPRR HPRR HPRR HPRR
mi/hr UF mi/hr UF
Fourth hr
HPRR HPRR
mi/hr UF
1.2 2.3
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complications, which may result in the loss of the transplant and
the death of the recipient.
Urinary fibrin degradation products (FDP): A 3-yr comparative
study. E. Schmitt, M. Seyfarth, R. Templin, P. Schneider, and H.
Klinkmann. Department of Medicine, Wilhelm Pieck University,
Rostock, German Democratic Republic. To elucidate the contro-
versial role of FDP, 1,050 analyses were carried out over a 3-yr
period in 112 patients with biopsy-proven glomerulonephntis
(GN), in 94 with urinary tract infection (UT!), and in 23 with renal
transplant rejections. When FDP were detectable, those with ac-
tive GN demonstrated a significant increase, averaging 12.3 jsg/ml
compared to those with inactive GN (averaging 1.3 jsg/ml). But
48.9% of active GN patients showed no urinary FDP, thus limiting
the test's diagnostic value. A similar observation was noted in the
94 cases of UTI where the FDP averaged 92 g/ml in acute cases,
compared to 1.3 rg/ml in nonacute cases. As in ON, UT! showed
a high (3 1%) incidence of false-positiveinegative results. FDP
values obtained before and during rejection in 23 renal allografts
confirmed the established observation that although elevated in
rejection, they do not provide evidence to predict rejection. Clini-
cally, urinary FDP appear to be of most value in those GN patients
with nephrotic syndrome (NS). Of those patients with NS resistant
to steroid therapy, FDP averaged 22.5 rg/m1 compared to an
average of 0.9 g/ml in NS patients sensitive to steroids. These
observations demonstrate that urinary FDP has a significant prog-
nostic value in predicting the effect of steroid therapy in NS.
Thyroid function in long-term hemofiltration. H. Schneider and
E. Streicher. Dept. Nephrology and Hypertension, Katharinen-
hospital Stuttgart, GFR. Fourteen patients with a dialysis prepe-
nod of 3 months to 7 yr have been treated with a 3 times weekly
hemofiltration schedule 4—21 months each; a total number of 1589
hemofiltrations were performed. As there exists no long-term
observation about thyroid function under maintenance hemofiltra-
tion, we compared T3—Ria, T4—Ria, and TSH at the beginning of
treatment and 4—21 months later and measured TSH, T3, and T4
response after i.v. injection of 200 tg TRF (Relefact®). Compara-
ble with previous reports, starting values of serum T3—Ria (mean:
92 23 ng/l0O ml; normal: 100—200 ng/100 ml) and serum T4—Ria
(mean: 4.94 1.79 Wl00 ml, normal: 4.5 — 13 rg/100 ml) were
found to be low. TSH values (mean: 3.48 0.47 U/ml) were in
the normal range (0—5 rU/ml). Dunng 4 to 21 months of treatment,
a continous decrease of thyroid hormone levels was observed.
Serum T3—Ria values fell significantly to 68 23 ng/100 ml, serum
T4—Ria values to 3.81 1.21 g/l00 ml. As serum TSH values in 8
of 10 patients decreased too (mean: 3.07 1.26 piml), a dysfunc-
tion in the hypothalamus-pituitary-thyroid axis is assigned. Stimu-
lation of the pituitary gland by injection of 200 jsg of TRF produced
in 7 of 10 patients a normal response (TSH elevation more than
50% of baseline value 20 mm postinjection was considered to be
normal): baseline TSH value (mean), 2.95 1.15 rU/ml; 20 mm
postinjection (mean) 5.72 2.59 U/ml. Parallel serum T3 showed
a marked increase: baseline T3 (mean), 64 24 ng/lOO ml; 20 mm
postinjection (mean) 90 37 ng/100 ml, whereas serum T4 values
slightly decreased: baseline T4 (mean), 4.08 1.20 j.tg/l00 ml; 20
mm postinjection (mean), 3.82 1.22 g/100 ml. Five hours post
TRF injection, TSH values returned nearly to normal (mean: 3.48
1.20 zU/m1), while serum T3 increased further to 129 29 ng/
100 ml and serum T4 elevated to 5.87 2.24 sg/l00 ml. These
findings might indicate a slowly developing hypothyroidism caused
by small but continuous losses of thyroid hormones (free and
protein bound) via the hemofiltrate, as there is no evidence of TSH
augmentation by continously decreasing serum T3 and T4 values
despite the normal response of the pituitary gland to TRF
stimulation.
Does long-term hemofiltration provoke secondary hyperpara-
thyroidism? H. Schneider, E. Streicher, H. Schmidt-Gayk. Dept.
Nephrology and Hypertension Katharinenhospital Stuttgart and
University Hospital Heidelberg, F.R.G. During the last 20 months,
14 patients have been treated with hemofiltration, 3—20 months
each, together 119 treatment months. A total number of 1469
hemofiltrations were performed in a 3-times-weekly schedule.
Four different hemolilters (Amicon, Berghof, Sartorius, RP 6)
were used in weight-controlled hemofiltration machines. Replace-
ment solutions administered venously had different electrolyte
compositions (mEq/liter):
Sol. A: Na 135, K 2.0, Ca 3.75, Mg 1.5, Cl 108.5, lactate 33.75.
Sol. B: Na 140, K 2.0, Ca 4.25, Mg 1.5, Cl 112, lactate 35.75.
Electrolytes in blood and hemofiltrate samples were analyzed in a
SMA 12 and aca autoanalyzer, iPTH, 25-OH-D and HCT were
measured by Ria methods. In mean values, 22.5 1.6 liters of
plasma water were exchanged, the medium fluid balance (N = 81)
was 3.46 1.02 liters (liters of replacement solution minus liters of
hemofiltrate). Ca balance studies admitting Sol. A showed a me-
dium Ca intake of 5.82 4.79 mEq, dependent from fluid balance
as indicated by moderate correlation (R = 0.501). Negative Ca
balance will occur, if fluid balance exceeds —5.9 liters. Admitting
Sol. B Ca intake increases (mean) to 9.62 4.80 mEq with weak
correlation to fluid balance (r = 0.329). Hemofiltration treatment
with Sol. A is not able to achieve adequate Ca intake (mediuml
week: 0.7 g); Sot. B restores approximately 1.05 glweek. Mg loss
averages —14.38 5.15 mEq with moderate correlation to fluid
balance (r = 0.597). Serum Mg values decrease —28.9% after 18
months of treatment. Phosphate elimination averages 846 251
mg slightly correlated to hemoflltrate volume (r = 0.459). iPTH
levels were found to increase 11—144% in 8 of 10 patients during 3—
20 months of hemofiltration treatment (Sol. A), 25-OH-D levels
decreased rapidly in 8 of 10 patients, and HCT remained mainly
unchanged. In hemofiltrate samples only traces of 25-OH-D and D-
binding protein were detected. As serum phosphate values were
maintained between 4.5—7.5 mg/tOO ml, we think the stimulation of
parathyroid secretion may be accounted for by a) Ca depletion
despite normal total serum Ca on expense of the skeleton using
Sol. A; b) small but continous losses of 25-OH-D and D-binding
protein via the hemoflltrate; c) continously decreasing serum Mg
values. We recommend a replacement solution with a Ca concen-
tration of 4—4.25 mEq/liter and a Mg concentration of 1.75—2.0
mEq/liter as well as oral supplements of Vit. D to compensate the
loss and thereby avoid stimulation of parathyroid secretion.
Hemofiltration (HF) with sorbent regeneration of ultrafiltrate
(SRU): First clinical experience in end-stage renal disease (ESRD).
S. Shaldon, M. C. Beau, G. Claret, G. Deschodt, P. Ramperez, C.
Mion. Dept. of Nephrology, University Hospital, Nimes, and
A.I.D.E.R., Montpellier, France. The promising results obtained
with post dilution HF prompted the development of SRU in closed
circuit for HF. The Amicon Diafilter TM3O produced ultrafiltrate
(UF) at a rate of 5—6 liters/hr with a blood flow of 300 mI/mm. The
UF was pumped through a bicarbonate-saturated Dl 1 Redy sor-
bent cartridge and then rewarmed, degassed, and reinjected (less
weight loss required) into the venous bubble trap. An in-line
polysulphone bacterial and pyrogen filter sited after the cartridge
removed urease pyrogen, bacteria, and carbon emboli. A syringe
pump delivered a constant infusion (4 ml/hr) of magnesium, cal-
cium, and potassium chloride to UF after the cartridge. Two
anuric ESRD patients (body WI, 78 and 59 kg) previously treated
by hemodialysis (6 mos) and HF:20 liters (acetate 40 mEq/liters) 3
x week (3 mos) have been treated for 2 months, 3 x week for 4 to
5 hr. Clinical status and tolerance of treatment compared to HF
remain unchanged and there have been no febrile reactions. Small
molecular solute control was similar to HF: mean serum urea pre
220, post 135 mg'lOO ml: creatinine pre 14.5, post 9.0 mg/l00 ml.
Serum electrolyte changes were similar except for an improvement
in acidosis with SRU. Serum HCO3 (HF) pre: 16.3 2.0, post:
19.5 1.5 mEq/liter; SRU pre: 19.6 1.8, post: 24.7 2.1 mEq/
liter. SRU permits HF without the need for sterile replacement
fluid or expensive balancing equipment. Limited experience sug-
gests equivalent results with a better correction of acidosis.
Nutritional blood flow to the limbs after access procedures. M.
H. R. Sheriff, R. B. Naik, D. J. Warren. Department of Nephrol-
ogy, University of Southampton, England. Many studies of total
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limb blood flow following vascular access procedures have shown
an increase in flow. We have measured the nutritional or capillary
flow in skin and muscle distal to arteriovenous fistulae and other
devices using a '33Xe clearance technique. Muscle blood flow
(MB F) in the hands of 18 nonuremic controls was 4.48 1.8 (SD),
and in 14 asymptomatic dialysis patients it was 2.94 1.19 ml 100
g1 min' (P < 0.05.). In 6 patients with cold hands, distal to
fistulae MBF was 1.32 0.18 and skin blood flow was reduced by
80%. In 4 patients with Sparkes-Mandril prostheses in the thigh,
MBF in the calf rose by only 28% in response to standard exercise
compared to 214% in the unoperated limb. Although access proce-
dures may increase limb blood flow through major vessels, it
seems likely that nutritional blood flow, especially in response to
exercise, may be reduced. The creation of large shunts in the legs
may greatly reduce exercise tolerance in dialysis patients.
Cerebral and hepatic urea (U) synthesis in patients with chronic
renal insufficiency (CR!). A. Tizianello, G. De Ferrari, G. Gari-
botto, and G. Gurreri. Servizio di Nefrologia, University of
Genoa, Italy. It is known that the liver is the major site of U
synthesis and that the brain also can produce U in some condi-
tions. However, the individual roles in ureogenesis of these organs
in CR1 are still obscure. We studied the sties of U production in
CR! by measuring the arterial-venous differences of U across the
hepato-splanchnic bed and the brain in 9 patients with CR1 (GFR,
10—26 mllmin; blood U, 15—26 mmole/liter; urinary U, 130—250
mole/min) and in 8 controls. Blood samples were collected simul-
taneously from a peripheral artery and from a hepatic vein (HV)
and/or an internal jugular vein (JV). U was determined enzymati-
cally in triplicate. In 5 out of 7 patients with CR!, no significant U
release into the HV was observed, whereas U was significantly
added to the iv in 6 out of 8 patients (308 56 mole/liter). On the
contrary, a significant U release into the HV (214 51 tmole/
liter), but not into the JV, was observed in all controls. In conclu.
sion, in CPJ the hepatic U production is markedly reduced, while a
striking cerebral U synthesis comes out; the latter could account
for the amount of U excreted with urine by the same patients.
Menstrual problems on hemodialysis: Sex hormone changes. V.
J. Wass, J. A. H. Wass, L. Rees, C. Edwards, C. S. Ogg. Dept. of
Nephrology, Guy's Hospital and Dept. of Endocrinology, St.
Bartholomews Hospital, London. Menstrual problems are com-
mon on regular hemodialysis (RDT), but there is little data on the
underlying hormonal abnormalities. The sequential changes in sex
hormones were studied over 3 months in 10 women aged 14 to 46
yr on home RDT (3 x 10 hr/week) for 0.5 to 6.7 yr. Serum was
taken weekly for progesterone (PROG), oestradiol (E2), follicle
stimulating hormone (FSH), luteinizing hormone (LH), prolactin(PRL), testosterone (1'), and sex hormone binding globulin
(SHBG). Three women had 2° amenorrhoea (>6 months) associ-
ated with either anorexia nervosa, marked hyperprolactinemia, or
the menopause. Only 1 woman menstruated regularly (27 day
cycle) and 6 had irregular menses (31 to >100 day cycle). Fifteen
cycles were studied. Two women had a mid-cycle rise in E2 but an
abnormally low luteal PROG. The others had no E2 or PROG
changes to indicate ovulation. Unexpectedly, 6 women had raised
T levels with normal SHBG. Follicular LH was raised in 2 women
but FSH levels were normal in all cases. These findings are typical
of polycystic ovary syndrome (POS). The other woman in this
group had a normal T but markedly raised LH and FSH levels
indicating that she was peiimenopausal. These 7 menstruating
women all had a raised PRL. The menses of one patient are now
regular (26 day cycle) following transplantation, and PRL, LH,
and T values are normal. Raised T levels may relate either to POS
or to hyperprolactineniia both of which cause menstrual distur-
bance. Treatment with either steroids or bromocriptine may be
possible.
Complement factors, degradation products, and immune com-
plexes after kidney transplantatiOn. E. Wegmhller, B. Frey, J.
Hodler, and F. Reubi. Medizinische Universithtspoliklinik, Berne,
Switzerland. In order to find out whether the complement system
is involved in rejection reactions occurring in renal allografts and
whether under these circumstances circulating immune complexes
are detectable, investigations were carried out in 20 kidney trans-
planted patients and 50 control subjects. Plasma and serum sam-
ples were studied daily for 3 weeks and twice weekly for the next 2
months after transplantation for the presence of complement fac-
tors (C3, C4, C3PA, Clq, properdin), degradation products (c3d, Ba)
and immune complexes. The complement factors and breakdown
products were determined by radial immunodiffusion, the immune
complexes by the labeled Clq binding assay. In the first 3 weeks
after kidney transplantation, C3 was decreased in all patients; C
was increased. The other complement factors displayed little
changes. The immune complexes were normal. Later on, all val-
ues normalized and remained stable, provided that no complica-
tion occurred. However, an acute rejection produced significant
changes. In 21 of 25 rejection reactions, C3 decreased whereas C
increased, indicating hypercatabolism of C3. Immune complexes
were not elevated and did not seem to participate in these reac-
tions. These findings are consistent with the activation of the
complement system during graft rejection. In contrast, immune
complexes do not seem to be involved in this situation.
Hemodialysis without heparin. H. F. Woods, S. Bunting, M. J.
Weston. Renal Unit, King's College Hospital, London. Prosta-
cydin, produced by vascular endothelium, is the most potent
inhibitor of platelet aggregation known to man. To assess its
effects on platelets during dialysis, ten greyhounds were dialyzed
for 90 mm with cuprophan coils. At the end of dialysis, arterial
platelet counts (% of initial value) were significantly higher in the
five dogs in which prostacydin had been infused (115.7 8.6) than
in the animals in which heparin alone had been used (77.8 16.8,
P <0.05). Prostacydin reduced the extraction of platelets by the
dialyzer. The screen filtration pressure, a measurement of platelet
aggregates in blood leaving the dialyzer, remained unelevated in
the prostacycin-treated animals (80 11.3 mm Hg) but rose
significantly in those infused with heparin alone (249 57 mm Hg,
P < 0.02). In another five dogs infused with prostacycin but no
heparin, dialysis did not reduce platelet count, elevate the screen
filtration pressure, or alter the overall clotting tests. Thus, prosta-
cydlin enables hemodialysis to be carried out without the unde-
sired effects on platelets and hemostasis that are associated with
the use of heparin.
